May 14, 2020 / 05:40PM GMT
Geoffrey Christopher Meacham - BofA Merrill Lynch, Research Division - Research Analyst
Okay. Welcome to the afternoon sessions of day 3 of the BofA Virtual Vegas Global Health Care Conference. My name is Geoff Meacham. I'm the senior biopharma analyst here at BofA. And I have Aspen Mori from my team as well on the line.
We're thrilled to have Amgen present this afternoon. And speaking on behalf of Amgen, we have Peter Griffith, CFO. We have Murdo Gordon, Head of Global Commercial Operations; and then Arvind Sood from the IR team.
Peter and Murdo, are you guys there?
Peter H. Griffith - Amgen Inc. - Executive VP & CFO
We sure are.
Geoffrey Christopher Meacham - BofA Merrill Lynch, Research Division - Research Analyst
Okay. Great. So the first thing we're going to do is I'll ask Peter and Murdo to have -- just say something at the onset here just to set up the stage. We have some questions and, of course, there are the ability to, on the Veracast system, to also type us a question and we can ask
Amgen Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot